Comparing NeuroPace (NASDAQ:NPCE) & Advanced Biomedical Technologies (OTCMKTS:ABMT)

Advanced Biomedical Technologies (OTCMKTS:ABMT) and NeuroPace (NASDAQ:NPCE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.

Volatility and Risk

Advanced Biomedical Technologies has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Comparatively, NeuroPace has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500.

Profitability

This table compares Advanced Biomedical Technologies and NeuroPace’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Advanced Biomedical Technologies	N/A	N/A	N/A
NeuroPace	-21.47%	-105.67%	-20.01%

Valuation & Earnings

This table compares Advanced Biomedical Technologies and NeuroPace”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Advanced Biomedical Technologies	N/A	N/A	N/A	N/A	N/A
NeuroPace	$99.99 million	5.57	-$21.47 million	($0.66)	-25.05

Advanced Biomedical Technologies has higher earnings, but lower revenue than NeuroPace.

Analyst Ratings

This is a summary of recent ratings for Advanced Biomedical Technologies and NeuroPace, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Advanced Biomedical Technologies	0	0	0	0	0.00
NeuroPace	1	1	4	2	2.88

NeuroPace has a consensus price target of $18.67, suggesting a potential upside of 12.93%. Given NeuroPace’s stronger consensus rating and higher possible upside, analysts clearly believe NeuroPace is more favorable than Advanced Biomedical Technologies.

Insider and Institutional Ownership

78.8% of NeuroPace shares are owned by institutional investors. 34.1% of Advanced Biomedical Technologies shares are owned by company insiders. Comparatively, 20.5% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

NeuroPace beats Advanced Biomedical Technologies on 7 of the 11 factors compared between the two stocks.

About Advanced Biomedical Technologies

Advanced Biomedical Technologies, Inc., a development stage company, designs, develops, manufactures, and markets biomaterial internal fixation devices. It offers polymer osteosynthesis devices, such as surgical screws, binding wires, rods, and related medical devices for the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, and related treatments, as well as for reconstructive dental procedures. The company was formerly known as Geostar Mineral Corporation and changed its name to Advanced Biomedical Technologies, Inc. in March 2009. Advanced Biomedical Technologies, Inc. was founded in 2002 and is based in New York, New York.

About NeuroPace

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.